235 related articles for article (PubMed ID: 14978873)
1. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
[TBL] [Abstract][Full Text] [Related]
3. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients.
Dales JP; Garcia S; Bonnier P; Duffaud F; Andrac-Meyer L; Ramuz O; Lavaut MN; Allasia C; Charpin C
Am J Clin Pathol; 2003 Mar; 119(3):374-80. PubMed ID: 12645339
[TBL] [Abstract][Full Text] [Related]
4. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
Dales JP; Garcia S; Bonnier P; Duffaud F; Meunier-Carpentier S; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
Int J Oncol; 2003 Feb; 22(2):391-7. PubMed ID: 12527939
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Zhou S; Wang GP; Liu C; Zhou M
BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression.
Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Hum Pathol; 2004 Feb; 35(2):176-83. PubMed ID: 14991534
[TBL] [Abstract][Full Text] [Related]
7. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma.
Zvrko E; Mikic A; Vuckovic L; Djukic V; Knezevic M
Otolaryngol Head Neck Surg; 2009 Oct; 141(4):478-83. PubMed ID: 19786216
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.
Meunier-Carpentier S; Dales JP; Djemli A; Garcia S; Bonnier P; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
Int J Oncol; 2005 Apr; 26(4):977-84. PubMed ID: 15753992
[TBL] [Abstract][Full Text] [Related]
10. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis.
Kumar S; Ghellal A; Li C; Byrne G; Haboubi N; Wang JM; Bundred N
Cancer Res; 1999 Feb; 59(4):856-61. PubMed ID: 10029075
[TBL] [Abstract][Full Text] [Related]
12. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905).
Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Taranger-Charpin C
Br J Cancer; 2004 Mar; 90(6):1216-21. PubMed ID: 15026804
[TBL] [Abstract][Full Text] [Related]
13. Endoglin (CD105) expression in endometrial carcinoma.
Saad RS; Jasnosz KM; Tung MY; Silverman JF
Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
[TBL] [Abstract][Full Text] [Related]
14. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays.
Charpin C; Dales JP; Garcia S; Carpentier S; Djemli A; Andrac L; Lavaut MN; Allasia C; Bonnier P
Clin Cancer Res; 2004 Sep; 10(17):5815-9. PubMed ID: 15355911
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.
Martone T; Rosso P; Albera R; Migliaretti G; Fraire F; Pignataro L; Pruneri G; Bellone G; Cortesina G
Oral Oncol; 2005 Feb; 41(2):147-55. PubMed ID: 15695116
[TBL] [Abstract][Full Text] [Related]
16. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
17. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
[TBL] [Abstract][Full Text] [Related]
18. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
19. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
Saad RS; Liu YL; Nathan G; Celebrezze J; Medich D; Silverman JF
Mod Pathol; 2004 Feb; 17(2):197-203. PubMed ID: 14657950
[TBL] [Abstract][Full Text] [Related]
20. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
